Objectives: In our previous study, we built a risk prediction model of vancomycin (VCM)-associated nephrotoxicity using decision tree (DT) analysis. However, this has several limitations in clinical applications. Our objective here was to construct a clinically applicable risk prediction model to be used at the time of initial therapeutic drug monitoring (TDM), in patients with uncomplicated infections.
Nephrotoxicity is a typical side effect of vancomycin (VCM). The incidence of VCM-associated nephrotoxicity was observed to be 5% to 43%, 1 and in our previous report, it was 14.7%. 2 VCM-associated nephrotoxicity is linked to prolonged hospitalizations, the need for renal replacement therapy, and increased mortality. 3 Thus, it is necessary to identify predictors of this important side effect to continue therapy for gram-positive bacterial infections such as methicillin-resis- Data mining is a method of extracting useful information from large datasets and displaying it in easy-to-interpret visualizations. 7 The objective of this method is to analyse information and to transform a complex dataset into understandable data, and to construct predictive models to assist decision making. 7 Decision tree (DT) analysis is a typical data mining technique comprising a flowchart-like tree framework, that is used to construct predictive models. 8 By following the flowchart, clinicians and pharmacists can estimate combinations of risk factors that may increase the risk of adverse drug reactions. 2, 8 Recently, several research reports encompassing DT analysis demonstrated its usefulness in the medical field. [9] [10] [11] However, there are few reports detailing the predictors of adverse drug reactions. 7 Hence, in our previous work, we demonstrated the usefulness of a DT model in the evaluation of adverse drug reactions. 2 In this study, we built a risk prediction model of VCM-associated nephrotoxicity and discovered that the predictive accuracy of the DT model was as accurate as the multiple logistic regression model (87.3%, respectively). However, the DT model built previously has several limitations with respect to clinical applications. Firstly, VCM trough concentrations were extracted individually as average values. Secondly, concomitant medications were extracted during the administration period.
Finally, the duration of therapy was included as a risk factor. Thus, the DT model included factors that could not be evaluated at the time it was to be used (for example, the beginning of drug administration or initial therapeutic drug monitoring [TDM] ).
By addressing these limitations, we anticipated that a more useful risk prediction model could be built. For instance, a clinically applicable DT model could be constructed by defining additional criteria as follows: (1) the timing of using the model could be set to initial TDM (by evaluating blood concentrations, a higher predictive accuracy could be obtained compared with the beginning of administration),
(2) risk factors that can be extracted at initial TDM should be evaluated, and (3) patient characteristics, such as the duration of therapy and the target trough concentration, could be normalized (for example, 7-14 days and 10-15 mg/L). In this study, we took these criteria into consideration: we set the optimal timing for application of the DT model for predicting and avoiding nephrotoxicity to be the time when initial TDM was conducted. The subjects to which this DT model was applied were defined as patients receiving VCM parenterally with a target trough level within 10.0 to 15.0 mg/L, based on the guidelines, 12,13 which was oriented toward uncomplicated infectious diseases. In addition, the patient characteristic of duration of therapy was normalized to 7 to 14 days as the duration of antimicrobial treatment is also recommended to be approximately 7 to 14 days, except in cases with complicated infections such as infective endocarditis, pneumonia, and meningitis. 14, 15 Thus, in this study, our objective was to construct a risk prediction model of VCM-associated nephrotoxicity, capable of being applied to clinical practice using for the timing of initial TDM and for uncomplicated infection patients.
2 | METHODS
| Patients
This research was a retrospective observation study conducted at Hokkaido University hospital. Subjects that had received VCM intravenously from November 2011 to April 2017 were extracted. All data were collected from the patients' medical records. Inclusion criteria were as follows: (1) aged 18 years and older, (2) the VCM trough concentration was measured after the third day of administration, (3) the dosing period was between 7 and 14 days (7 days or more to 14 days or less), and (4) the target trough concentration at the initial TDM was 10 to 15 mg/L. Patients who underwent renal replacement therapy (hemodialysis or continuous hemodiafiltration), or had nephrotoxicity before the VCM trough concentration was measured were excluded.
The criteria of nephrotoxicity were defined as an increase in serum creatinine (Scr) of at least 0.5 mg/dL or 50% or higher from the baseline. 1 In order to evaluate VCM-associated nephrotoxicity, we extracted the maximum Scr during the administration period.
Risk factors for nephrotoxicity were extracted from the beginning of administration until the day of the initial TDM. They were extracted based on previous studies, as follows 1,2,4-6 : patient age, gender (male/ female), body weight, body mass index, Scr on the day of the initial TDM, creatinine clearance (CCr) on the day of the initial TDM, concomitant medications (NSAIDs, furosemide, amphotericin B, aminoglycosides, PIPC-TAZ, and vasopressor drugs), residence in the intensive care unit, with loading dose and initial VCM trough concentration ≥ 15 mg/L. Among the concomitant medications, vasopressor drugs were defined as follows: etilefrine, noradrenaline, olprinone, milrinone, dopamine, and dobutamine. 16 The loading dose was defined as "the initial dosage (single or daily) was 1.25 times or more of the maintenance dosage. 16 
"
In addition, for evaluating patient characteristics, the number of days to reach maximum Scr, the frequency of TDM during the administration period, the days to initial TDM, the days to maximum Scr, the maximum VCM trough concentration during therapy, and the duration of therapy were extracted. 
| Construction of the DT model and statistical analysis
The DT analysis was performed using the chi-squared automatic interaction detection (CHAID) algorithm. 8, 9 In the DT model, the dependent variable was defined as the presence or absence of nephrotoxicity, and the independent variable was extracted from risk factors. CHAID is a non-parametric procedure that ensures that no assumptions are made of the underlying data. The CHAID algorithm creates multiple 2 × 2 contingency tables between dependent variables and each independent variable, which selects the most significant independent variable in a chi-squared test, and branches the tree. 8, 9 The detection was run in duplicate with parent nodes defined at 20 subjects, child nodes defined at 10 subjects, and significance set at (amerge, asplit, and P value) ≤0.05.
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The subgroups constructed by the DT model were divided into three classification groups according to the risk of nephrotoxicity, low-, intermediate-, and high-risk groups. In previous reports, the incidence of nephrotoxicity was variable, ranging from 5% to 43%. 1 However, in a systematic review, van Hal et al reported that out of 15 studies, 10 had an incidence of nephrotoxicity of 10% to 25%. 20 Our previous research supports this result (14.7%). 2 Thus, based on the incidence of nephrotoxicity, the subgroups were defined as follows: (1) low-risk group (<10%), (2) intermediate-risk group (10%-25%), and (3) a high-risk group (>25%).
Comparisons of the patient characteristics were unpaired, and all tests of significance were two-tailed. Continuous variables were compared using the Mann-Whitney U test. Categorical variables were compared using Pearson's chi-square or Fisher's exact test. P ≤ 0.05 was considered statistically significant.
To validate the splitting variables extracted by DT analysis, multiple logistic regression analysis was performed. In this analysis, all the potential risk factors were applied based on the univariate analysis (P < 0.1). A stepwise approach was used to enter new terms into the multiple logistic regression analysis. Nephrotoxicity was the dependent outcome variable, and 0.05 was set as the limit for the acceptance or removal of new terms. The Hosmer-Lemeshow test was used to evaluate the fitness of the logistic regression model. 21 For the DT and logistic regression analysis, all continuous variables were converted into categorical variables except for the initial VCM trough concentration ≥ 15 mg/L. The cut-off values were set to the point on the recipient operation characteristic curve closest to (0, 1). 22 All statistical analyses were performed using SPSS Statistics Version 24 (IBM, Tokyo, Japan).
| Model development and evaluation
To evaluate the misclassification risk of the DT model, the 10-fold cross-validation method was adopted. In this method, the original sample is randomly partitioned into 10 equal-sized subsamples.
Among the 10 subsamples, one is retained as the validation data, and nine are used as the training data. The cross-validation is repeated 10 times, with each of the 10 subsamples used exactly once as the validation data. The averaged value of the 10 results from the folds is estimated as the misclassification risk value. Moreover, multiple logistic regression analysis was used to compare the accuracy of the DT analysis as the conventional statistical method.
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| Ethics
This study was carried out in accordance with the guidelines for the care for human study, and the study protocol was approved by the ethics committee of the Hokkaido University Hospital (study protocol NO. 017-0141).
3 | RESULTS
| Patient characteristics
As shown in Figure 1 , out of 1065 patients, 402 were included in the study. Their characteristics are shown in Table 1 . Fifty-six (13.9%) patients developed nephrotoxicity.
A comparison of patient characteristics is shown in Table 2 .
Patients that developed nephrotoxicity differed significantly from those that did not with respect to furosemide use, PIPC-TAZ use, vasopressor drug use, days to maximum Scr, and initial and maximum VCM trough concentrations.
The concomitant medications aminoglycosides and amphotericin B were excluded from the analysis of risk factors, as the number of cases was too low to perform DT analysis.
| DT analysis
As shown in Figure 2 , based on the CHAID algorithm, four predictive variables were automatically extracted using DT analysis to produce a total of six subgroups. The order of the splitting variables was determined by order of the strength of the relationship to nephrotoxicity. 
| Multiple logistic regression analysis
In the univariate analysis (Table 3) , the adjusted CCr ≥ 92.6 mL/min, concomitant medications (furosemide, PIPC-TAZ, and vasopressor drugs), and the initial VCM trough concentration ≥ 15.0 mg/L were applied to the multiple logistic regression analysis (P < 0.1).
In the multiple logistic regression analysis (Table 4) , these factors (except for the adjusted CCr ≥ 92.6 mL/min) were extracted as the independent predictors of nephrotoxicity. The Hosmer-Lemeshow test gave a P-value of 0.70.
| Validation of the DT model
The misclassification risk of the DT model, estimated by 10-fold crossvalidation, was 13.9% ± 1.7%. The predictive accuracies of the DT and logistic regression models were 87.1% and 86.1%, respectively.
| DISCUSSION
In this study, we built a risk prediction model of VCM-associated nephrotoxicity using DT analysis. The timing of using the model was set to initial TDM. The inclusion criteria, in addition to those used in previous research, were as follows: (1) the target trough level of VCM was set to 10 to 15 mg/L, and (2) the duration of therapy was 7 to 14 days. Subjects were also assumed to have uncomplicated With nephrotoxicity, n (%) 56 (13.9)
SD, standard deviation. Thus, as this target trough level and duration of therapy of VCM is commonly achieved in our hospital, the DT model is expected to be widely applicable.
In the present study, 56 (13.9%) patients developed nephrotoxicity, which was similar to a previous report. 20 However, this incidence was lower than in our earlier study (14.7%). 2 This result was probably due to the exclusion of patients with a duration of therapy >14 days and a target trough range set to 15 to 20 mg/L.
In the DT and logistic regression models, the same four factors were extracted as splitting variables and independent predictors. Of these, three factors (concomitant medications [furosemide and vasopressor drugs] and VCM trough concentration ≥ 15.0 mg/L) were the same as in our previous study, 2 and these are consistent with earlier studies. 1 Recently, it was reported that concomitant use of PIPC-TAZ with VCM increases the probability of nephrotoxicity. 4 Based on this,
we also extracted the use of PIPC-TAZ as a factor and the odds ratio (OR: 3.83, 95% CI: 1.80-8.11) obtained was similar to that reported in a systematic review (unadjusted OR: 3.12, 95% CI: 2.04-4.78). 4 In the DT model, we divided six subgroups into three classification groups according to the risk of nephrotoxicity. Two subgroups were extracted as the high-risk group. First, patients with initial VCM trough concentrations of ≥15.0 mg/L and who were using vasopressor drugs were classified. The incidence of nephrotoxicity in these subjects was 70.0%. Patients using vasopressor drugs have unstable hemodynamics, and their renal function tends to fluctuate. Thus, this subgroup was estimated to be a "very high-risk group," and it is suggested that clinicians and pharmacists pay these patients the most attention with respect to nephrotoxicity. Secondly, patients with initial VCM trough concentrations of ≥15.0 mg/L, not using vasopressor drugs but who were using furosemide, were classified as another high-risk group.
Our data suggest that 38.9% of these patients will develop nephrotoxicity. Although the number of patients within each subgroup was small, the results are consistent with our previous studies (incidences of nephrotoxicity of 69.6% and 43.2%, respectively). 2 As a low-risk group, patients with initial VCM trough concentrations of <15.0 mg/ L, which were not using either furosemide or PIPC-TAZ (that is, they did not have any risk factors), were also classified. The incidence of nephrotoxicity in these subjects was lower than previously reported. 20 Furthermore, the number of cases in the low-risk group was 211 (52.5%). Thus, our study has shown that approximately 50% of patients were using VCM relatively safely. Other patients were classified into intermediate risk groups. The incidence of nephrotoxicity was 16.3% to 21.3%, similar to data reported in a systematic review (10%-25%). 20 The method for validating the DT model has not been well established. In our study, logistic regression analysis was adopted as the conventional statistical method, and we compared the accuracies of the two models. 23, 24 As a result, the predictive accuracies of the DT and logistic regression models were also similar (87.1% and 86.1% respectively). These accuracies and the misclassification risk of the DT model (13.9% ± 1.7%) are considered favourable. 2, 11, 23, 25 In the multiple logistic regression analysis, the Hosmer-Lemeshow test gave a P-value of 0.70, indicating a good fit. 21 The results of DT and logistic regression analyses were also similar to the previous study. 2 However, these results were considered as new findings. For this reason, in the previous study, we aimed to demonstrate the usefulness of a DT model in the evaluation of adverse drug reactions. 2 On the other hand, the present research was aimed at establishing a model applicable to clinical practice, such as setting the "timing of model use" and "target patient characteristics." Therefore, our results were considered to be different from the previous ones. In the present study, we built a risk prediction model of VCMassociated nephrotoxicity. By following this flowchart-like model, it is possible to estimate the probability of adverse drug reactions easily and quantitatively, considering combinations of multiple risk factors. 2, 8 In contrast, the logistic regression model can estimate the independent risk factors as OR. 21 From the point of view of clinical application, it is considered that the DT model is superior to the logistic regression model.
The antibiotic stewardship (AS) program guidelines 26 recommend proactive intervention and feedback as one of its core strategies. The guidelines propose that constructing facility-specific clinical practice Moreover, our study has several limitations. First, the DT model was constructed using single-center clinical data. Therefore, its clinical application must be carefully monitored. As a next task, a larger clinical study such as a multi-center trial will be required. Second, in this study, an initial VCM trough concentration of ≥15.0 mg/L was extracted as a risk factor in DT and logistic regression models. A high trough concentration of VCM was the most common risk factor of nephrotoxicity. 1 However, the possibility of "nephrotoxicity-induced high trough concentration" could not be ruled out. Therefore, it is unclear whether high trough concentrations are the cause or the result of nephrotoxicity. This is a common limitation of almost all previous studies. 1, 2, 6, 20 In addition, based on the previous report, we defined the criteria of nephrotoxicity as an increase in Scr of at least 0.5 mg/dL or 50% or higher from the baseline. 1 These criteria were also consistent with Stage 1 of acute kidney injury defined in the Kidney Disease Improving Global Outcomes guideline. 28 Considering that stage 1 is the mildest acute kidney injury in the Kidney Disease Improving Global Outcomes, there is a need to build a prediction model for more severe nephrotoxicity in future research. Finally, we could not evaluate several factors, particularly the diagnosis of infections and underlying diseases. For this reason, for some of the patients, it was difficult to extract the diagnosis (for example, site of infection that may influence the target VCM concentration). We would be unable to construct a DT model if these patients were excluded. In the present study, as an alternative index, we used the target trough range and the administration period. In future research, it will be necessary to take into consideration whether the detailed diagnosis of a patient's infectious diseases indicates a complicated infection (for example, infective endocarditis, pneumonia, or meningitis).
Generally, the number of factors that can be analysed by multivariate logistic regression analysis depends on the number of patients who developed adverse drug reactions. In particular, it is required 10 times or over of the number of factors. 29 In the present study, 56 patients developed nephrotoxicity, and five factors were applied to the multiple logistic regression analysis, thereby implying that sufficient cases were obtained. On the other hand, in the DT model, the number of factors that can be analysed also depends on the stopping criteria of branches. 10, 19 In addition, the correlations between risk factors are related. For example, if the same factor is extracted in the second branches (tree is divided into four subgroups), which is extracted only two risk factors. Finally, a large clinical study will be required to analyse more risk factors.
| CONCLUSION
In this study, we successfully built a risk prediction model of VCMassociated nephrotoxicity to be used at the time of initial TDM in patients with uncomplicated infections. This novel flowchart-like tree model was developed for use in clinical applications. It is anticipated that this model will improve the prediction of adverse drug reactions and assist in clinical decision making.
